[New York, NY, 13 December 2012]
Analysis of Health R&D Pipeline Shows Important Progress, but Significant Gaps in Innovation Remain
Despite important progress in research and development (R&D) for global health over the past decade, only a small fraction of new medicines developed between 2000 and 2011 were for the treatment of neglected diseases, highlighting the ‘fatal imbalance’ between global disease burden and drug development for some of the world most devastating illnesses, said Doctors Without Borders/Médecins Sans Frontières (MSF) and the Drugs for Neglected Diseases initiative (DNDi), in an analysis to be presented today at an international conference aimed at spurring medical innovations for these diseases.
[Deutsch] [Español] [Português]
[New York, NY, 13 December 2012]
[Geneva, Switzerland, 11 December 2012]
Grant to help expedite 4-in-1 ARVs adapted for babies and toddlers with HIV/AIDS, including those co-infected with tuberculosis
The Drugs for Neglected Diseases initiative welcomes the announcement by UNITAID to grant up to USD 17.3 million to the organization for its paediatric HIV programme. The grant, to be disbursed over three years, will enable DNDi and partners to build on the advances made in the field of paediatric HIV to date, and drive specific research and development to deliver child-adapted ARV formulations that do not require refrigeration, are easy-to-administer and palatable, with simplified dosing, and which can be given to children co-infected with tuberculosis.
[Geneva, Switzerland and Kinshasa, Democratic Republic of the Congo – 6 December 2012]
Phase II/III Clinical Trial Launched in the Democratic Republic of the Congo and Central African Republic
A new oral‐only treatment for sleeping sickness has entered Phase II/III clinical study in patients with late‐stage sleeping sickness in the Democratic Republic of the Congo (DRC) and soon in Central African Republic (CAR). The study, initiated by the Drugs for Neglected Diseases initiative (DNDi) and its partners, will test the efficacy and safety of fexinidazole, with once daily tablets for ten days.
[New York, USA/Geneva, Switzerland – 30 November 30 2012]
Age-appropriate formulations of antiretroviral drugs urgently need to be developed and delivered to save the lives of babies and toddlers living with HIV/AIDS
The Drugs for Neglected Diseases initiative (DNDi) welcomed the US President’s Emergency Plan for AIDS Relief (PEPFAR)’s new ‘PEPFAR Blueprint: Creating an AIDS-Free Generation,’ released by US Secretary of State Hillary Clinton in advance of World AIDS Day, and its focus on ensuring ambitious scale-up of treatment and diagnosis for people with HIV/AIDS, including children living with HIV/AIDS.
Watch “Children living with HIV/AIDS: the reality of a neglected disease”, a short film on the daily life of a mother with an infected child in South Africa
[Geneva, Switzerland – 13 November 2012]
DNDi screens MMV’s open access Malaria Box, leading to three potential drug classes to treat sleeping sickness and leishmaniasis, which threaten the lives of millions throughout sub-Saharan Africa and pockets around the world
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi’s screening of MMV’s open access Malaria Box. The resulting DNDi screening data are among the first data generated on the Malaria Box to be released into the public domain, exemplifying the potential of openly sharing drug development data for neglected patients.
[Geneva, Switzerland; Atlanta, GA, USA – 12 November 2012]
Wellcome Trust to fund three-year study in Texas to look for new biological markers measuring treatment efficacy for the leading parasitic killer of the Americas
Today at the 61st Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), the Drugs for Neglected Diseases initiative (DNDi) announces a new USD 3 million Strategic Translation Award from the Wellcome Trust to identify new biological markers for the evaluation of treatment efficacy in Chagas disease, a potentially fatal neglected tropical disease.
[New York, USA, Geneva, Switzerland – 8 November 2012]
Doctors Without Borders/Médecins Sans Frontières, Drugs for Neglected Diseases initiative, Mount Sinai School of Medicine’s Global Health Program Convene Medical Experts from Around the World for New York Conference
Meeting the lifesaving needs of people left behind by the global health revolution will be the focus of a major medical conference in December in New York, held by Doctors Without Borders/Médecins Sans Frontières (MSF), the Drugs for Neglected Diseases initiative (DNDi), and Mount Sinai School of Medicine’s Global Health Program.
[Kuala Lumpur, Malaysia, Mumbai, India, and Geneva, Switzerland – 3 October 2012]
Cipla, one of the leading generic pharmaceutical companies, along with the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) today announced the prequalification of the fixed dose combination (FDC) of Artesunate (AS) and Mefloquine (MQ) – ASMQ FDC – by the World Health Organization (WHO). This Cipla-manufactured ASMQ FDC is the first artesunate-mefloquine FDC to be prequalified by WHO and is recommended for the treatment of malaria.
[Rio de Janeiro, 23 September 2012]
At the opening ceremony of the XVIII International Congress for Tropical Medicines and Malaria (ICTMM) and the XLVIII Congress of the Brazilian Society of Tropical Medicine in Rio de Janeiro, the Ministry of Health of Brazil signed a Cooperation and Technical Assistance Agreement with the Oswaldo Cruz Foundation (FIOCRUZ) and the Drugs for Neglected Diseases initiative (DNDi) Latin America, uniting the three actors in a strategic partnership to collaborate on research and development (R&D) for new therapies and diagnostics for neglected diseases.
[Washington, DC; Geneva; Mumbai – 20 July 2012]
On the eve of the XIX International AIDS Conference in Washington, DC, the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, announced a new collaboration with Indian drug manufacturer Cipla to develop and produce an improved first-line antiretroviral (ARV) combination therapy specifically adapted to meet the treatment needs of infants and toddlers living with HIV/AIDS. Once delivered, this new paediatric ARV combination could help to accelerate the provision of care to the world’s youngest children living with HIV/AIDS, who are at very high risk of dying without treatment. An estimated 3.4 million children have HIV/AIDS, but less than a quarter currently have access to antiretroviral therapy (ART), compared with 54% for adults. Without treatment, more than half of children with HIV/AIDS will die before their second birthday, and 80% will die before they turn five.
[Geneva, Switzerland, June 29, 2012]
Dr Graeme Bilbe to Lead DNDi’s R&D Efforts to Address the Treatment Needs of the Most Neglected Patients
The not-for-profit research and development (R&D) organization Drugs for Neglected Diseases initiative (DNDi) announces the appointment of its new R&D Director, Dr Graeme Bilbe, previously with Novartis. With this move, Bilbe brings his vast experience in drug discovery and development to the field of neglected diseases.
Listen to Dr Bilbe’s podcast on DNDi‘s R&D challenges
[Geneva, Switzerland, June 21, 2012]
Award recognizes importance of investing in scientific research around the world
The University of Dundee awarded Dr Bernard Pécoul, Executive Director of the Drugs for Neglected Diseases initiative (DNDi), with an honorary Doctor of Laws Degree (LLD).This week, the University of Dundee awards a Doctor of Laws Degree (LLD) to eleven leading figures from fields including medicine, research, life sciences, law, art, and extreme adventure. University of Dundee Principal, Professor Pete Downes, considers the recipients, among whom Dr Bernard Pécoul, to be ‘among the highest achievers, clearest thinkers, and most respected voices in their fields’.
[Tokyo, Japan and Geneva, Switzerland, June 12, 2012]
Astellas Pharma Inc. (Tokyo:4503, ”Astellas”) and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness – three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide. The agreement is a first critical step in Astellas’ new strategy to enter into the field of NTDs, with DNDi as its first partner.
[Geneva, Switzerland – 21 May 2012]
DNDi Welcomes World Health Organization Expert Recommendations to Begin Negotiations for an R&D Convention at the World Health Assembly
After a decade-long process of analysis and deliberations on ways to better address the health needs of developing countries, a recently released report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) will be discussed this week at the 65th World Health Assembly (agenda item 13.14). The Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, welcomes the experts’ conclusion that ‘the time has now come for WHO Member States to begin a process leading to the negotiation of a binding agreement on R&D relevant to the health needs of developing countries’.
[Mumbai – Geneva– 24th April 2012]
On the occasion of World Malaria Day, Cipla, one of the world’s leading generic pharmaceutical companies in collaboration with Drugs for Neglected Diseases initiative (DNDi) announced the forthcoming launch of the Fixed-Dose combination of ‘Artesunate (AS)1 + Mefloquine (MQ)2’ for the treatment of uncomplicated P. falciparum malaria. There were an estimated 216 million cases of malaria globally in 2010.
[Boston, USA and Geneva, Switzerland – 12 April 2012]
AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide. Novel drug candidates to emerge from this collaboration will bolster the drug development pipeline for new medicines urgently needed by millions of patients.
[Geneva, Switzerland – 12 March 2012]
The Drugs for Neglected Diseases initiative (DNDi) has received a EUR 2 Million Strategic Translation Award from the Wellcome Trust to develop the azole compound E1224, a promising drug to treat Chagas disease being tested in adult patients in Bolivia. The Award, the first that DNDi has received from the Wellcome Trust, will take the project to the end of Phase II clinical trials.
[Geneva, Switzerland – 12 March 2012]
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
[Geneva, Switzerland – 30 January 2012]
On the occasion of today’s high-level event in London, ‘Uniting to Combat Neglected Tropical Diseases,’ organized in support of the new World Health Organization (WHO) Neglected Tropical Disease (NTD) 2020 Roadmap, the Drugs for Neglected Diseases initiative (DNDi) welcomes the commitments from various partners and emphasizes that filling the major gaps in research and development (R&D) to develop new treatment and diagnostic tools is key to effectively support elimination or control of targeted NTDs by 2020. [Deutsch] [Español] [Português] [Japanese]
[London – 30 January 2012]
Partners pledge innovative, coordinated action aimed at new World Health Organisation goals
Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade.